Ascend Bio aims to transform the lives of patients with life-threatening metabolic and respiratory diseases. They have developed an optimized synthetic biology technology platform to generate new classes of highly functional curative cell therapy medicines by the Integrated Programming of stem cells.
Their revolutionary integrated cell programming platform technology combines growth factor-directed differentiation and genetic forward programming. This synthetic biology approach allows for the generation of mature therapeutic cell types with unprecedented function and scalability. The core technology has been validated by successfully producing therapeutic-grade liver cells that display superior performance, including crucial cytochrome P450 enzyme activities.
Status | Active |
Website | https://www.ascendbiotx.com/ |
Category | Biotech |
Modality | Cell therapy |
Therapautics Area | Multi-therapeutics |
Headquaters | Cambridge, UK |
Partner | University of Cambridge |
Investment Portfolio | Fund Investment |
Co-Investors | Oxford Technology |